Get started
Author

D. S. Korobko

Observed names: D S Korobko, D. Korobko, D. S. Kasatkin, D.S. Korobko, Denis Korobko, Denis S Korobko, Denis S. Korobko, Denis Sergeevich Korobko, Д С Коробко, Д. С. Коробко, Д.С. Коробко, Коробко Д. С., Коробко Д.С., Коробко Денис Сергеевич
ORCID: 0000-0002-7938-3782
Observed ORCID: 0000-0002-7938-3782
OpenAlex ID: A5026809525
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
2017 · James F Howard, Kimiaki Utsugisawa, et al. · The Lancet Neurology · 884
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
2021 · James F Howard, Vera Bril, et al. · The Lancet Neurology · 782
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
2023 · Vera Bril, Artur Drużdż, et al. · The Lancet Neurology · 317
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)
2024 · James F. Howard, Tuan Vu, et al. · Neurotherapeutics · 69
PDF
Genome-wide significant association with seven novel multiple sclerosis risk loci
2015 · Christina M Lill, Felix Luessi, et al. · Journal of Medical Genetics · 43
PDF
Association of SNPs of CD40 Gene with Multiple Sclerosis in Russians
2013 · Ekaterina Alekseevna Sokolova, Nadezhda Alekseevna Malkova, et al. · PLoS ONE · 37
PDF
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study
2025 · Vera Bril, Artur Drużdż, et al. · Journal of Neurology · 15
Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy
2022 · V. S. Krasnov, K. Z. Bakhtiyarova, et al. · Neurology neuropsychiatry Psychosomatics · 14
PDF
Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia
2022 · A. N. Boiko, K. Z. Bakhtiyarova, et al. · Neurology neuropsychiatry Psychosomatics · 10
PDF
Validation of Russian-language version of the Expanded Disability Status Scale (EDSS) for patients with multiple sclerosis in the Russian Federation
2023 · A.D. Stepanova, E.P. Evdoshenko, et al. · Medical Technologies Assessment and Choice · 9
Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
2019 · Evgeniy Evdoshenko, Alexandra Stepanova, et al. · PLoS ONE · 8
PDF
Multiple sclerosis: modern diagnostic markers and prognostic factors of disease progression
2024 · A. I. Prokaeva, I. E. Arkhipov, et al. · Сибирский научный медицинский журнал · 7
PDF
CLIPPERS: Multiparametric and quantitative MRI features
2022 · Alexandra M. Korostyshevskaya, Julia A. Stankevich, et al. · Radiology Case Reports · 7
Clinical and epidemiological aspects of neuromyelitis optic spectrum diseases in the russian population
2021 · T.O. Simaniv, I.A. Kochergin, et al. · S S Korsakov Journal of Neurology and Psychiatry · 6
Polymorphic locus rs10492972 of the KIF1B gene association with multiple sclerosis in Russia: Case control study
2011 · Ekaterina A. Kudryavtseva, Aleksei S. Rozhdestvenskii, et al. · Molecular Genetics and Metabolism · 6
Discovering predictive features of multiple sclerosis from clinically isolated syndrome with machine learning
2024 · Minh Sao Khue Luu, Bair N. Tuchinov, et al. · Artificial Intelligence in Health · 5
Local experience of IL-6 pathway inhibition with satralizumab for patients with neuromyelitis optica spectrum disorder
2022 · L.N. Prakhova, V.S. Krasnov, et al. · S S Korsakov Journal of Neurology and Psychiatry · 5
Polymorphic variants of the immune response genes as risk factors for primary progressive multiple sclerosis
2017 · E. V. Popova, I. S. Kiselev, et al. · S S Korsakov Journal of Neurology and Psychiatry · 5
A retrospective analysis of the effect of pregnancy on the course of multiple sclerosis
2015 · E. V. Popova, D. S. Korobko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 5
Consensus of expert advices on routing, diagnosis, and management of patients with neuromyelitis optica spectrum disorders
2021 · A. N. Boyko, K. Z. Bakhtiyarova, et al. · Neurology neuropsychiatry Psychosomatics · 4
PDF
Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis
2016 · Marina Tiumentseva, Vera Morozova, et al. · Immunogenetics · 4
[The effect of genetic factors on the phenotypic expression of multiple sclerosis].
2013 · D S Korobko, N A Malkova, et al. · PubMed · 4
Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
2025 · A. N. Boyko, M. N. Zakharova, et al. · Neurology neuropsychiatry Psychosomatics · 3
PDF
The first experience with the use of ofatumumab for the treatment of pediatric multiple sclerosis in real-life clinical practice in Russia. A case series
2025 · E. D. Kuzminykh, V. M. Lebedev, et al. · Neurology neuropsychiatry Psychosomatics · 3
PDF
POEMS-syndrome
2023 · I.E. Arkhipov, I.Yu. Vergunova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 3
Works count: 78
Citation count: 2,273
H-index: 9
I10-index: 9
Year
Topic
Type